NCT07097389View on ClinicalTrials.gov

In Vivo Human Study on Commercial Cellobiose as a Potential Prebiotic Candidate

NACompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

June 1, 2025

Conditions
Gut -MicrobiotaAs a Preliminary Study, Healthy Population's Gut Microbiota is Studied to See if Cellobiose Supplementation is Altering the Microbial Community or Not
Interventions
DIETARY_SUPPLEMENT

Cellobiose

Cellobiose powder (Savanna Ingredients GmbH), 5 g per day and 10 g per day, mixed into \~200 mL water and taken orally with breakfast for the first 7 days and the rest of the 21 days.

DIETARY_SUPPLEMENT

Oligofructose P95

Oligofructose (Orafti® P95, Beneo GmbH), 5 g per day and 10 g per day, dissolved in \~200 mL water and taken orally with breakfast for the first 7 days and the rest of the 21 days.

DIETARY_SUPPLEMENT

Maltodextrin (Placebo)

Maltodextrin powder (Special Ingredients Limited), 5 g per day and 10 g per day, dissolved in \~200 mL water and taken orally with breakfast for the first 7 days and the rest of the 21 days.

Trial Locations (1)

RG6 6DX

University of Reading, Reading

All Listed Sponsors
lead

Manxi Huang

OTHER

NCT07097389 - In Vivo Human Study on Commercial Cellobiose as a Potential Prebiotic Candidate | Biotech Hunter | Biotech Hunter